AtaiBeckley Completes Redomiciliation from Netherlands to U.S.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 31 2025
0mins
AtaiBeckley announced the completion of the redomiciliation of the parent company of the AtaiBeckley group from a Netherlands company to a U.S. entity incorporated in Delaware. The redomiciliation was approved by approximately 99% of the votes cast at the Company's extraordinary general meeting of shareholders on November 4, 2025. The redomiciliation was completed following the close of trading on the Nasdaq Global Market on December 30, 2025. At completion, all issued and outstanding ordinary shares of Atai Beckley N.V. were exchanged on a one-for-one basis for newly issued shares of common stock of the Delaware company, AtaiBeckley Inc. The former shareholders of Atai Beckley N.V. are now the stockholders of the Delaware company. AtaiBeckley Inc's common stock will continue to trade on NASDAQ under the trading symbol "ATAI".
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATAI
Wall Street analysts forecast ATAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATAI is 13.13 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.840
Low
10.00
Averages
13.13
High
16.00
Current: 3.840
Low
10.00
Averages
13.13
High
16.00
About ATAI
AtaiBeckley Inc. is a clinical-stage biotechnology company focused on transforming patient outcomes by developing rapid-acting and convenient mental health treatments. The Company's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (oral R-MDMA) for social anxiety disorder, which are in Phase 2 clinical development. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is being developed to produce rapid treatment effects from a single dose, within a two-hour interventional psychiatry treatment paradigm, and with a favorable safety profile. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with treatment-resistant depression (TRD). EMP-01 is an oral formulation of R-MDMA.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AtaiBeckley Provides 2026 Outlook with Accelerated Drug Development Plans
- Strategic Restructuring: AtaiBeckley enters 2026 with significant momentum following the merger of atai Life Sciences and Beckley Psytech and its redomiciliation to the U.S., which is expected to drive innovation in mental health treatments.
- Clinical Progress: BPL-003 demonstrated significant antidepressant effects in its Phase 2 trial for treatment-resistant depression, with plans to initiate a Phase 3 trial in Q2 2026, further validating its efficacy.
- Patent Protection: The new patent for EMP-01 was granted in December 2025, expected to provide market exclusivity until 2043, enhancing the company's competitive position in treating social anxiety disorder.
- Cost Savings: The completion of the redomiciliation from the Netherlands to the U.S. is anticipated to simplify corporate structure and reduce administrative burdens, thereby providing greater financial flexibility for future growth.
Continue Reading
GH Research Secures FDA Clearance for GH001 Clinical Trial
- FDA Approval: The U.S. FDA lifted the clinical hold on GH Research Plc's GH001 trial, enabling the company to advance this potential ultra-rapid treatment for treatment-resistant depression, marking a significant milestone.
- Trial Progress: In February 2025, GH001's Phase 2b trial met its primary endpoint, demonstrating a significant reduction of 15.2 points in the Montgomery-Åsberg Depression Rating Scale (MADRS) on Day 8, compared to a 0.3 point increase in the placebo group, indicating its strong antidepressant effect.
- Market Outlook: GH Research anticipates initiating its global pivotal program in 2026, with the CEO stating that discussions with the FDA will align the design for the Phase 3 trial, further propelling the product's market entry.
- Stock Reaction: GH Research shares surged 34.52% to $17.86 at the time of publication, reflecting positive market sentiment towards the FDA approval and optimistic expectations for future growth.
Continue Reading